Evidence map›Paper›PMID 40553939›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2025

Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract.

Rayan Rammal, Florestan J Koll, Ziyu Chen, Jacob E Tallman, Syed Muneeb Alam, Jordan E Eichholz, Walid Chatila, Tejiri Agbamu, Andrew T Lenis, Merve Basar and 19 more

Abstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Rayan RammalDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Florestan J KollDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Urology, University Hospital Frankfurt, Goethe University, Frankfurt Am Main, Germany; German Cancer Consortium (DKTK), DKFZ, University Hospital Frankfurt, Frankfurt, Germany.
Ziyu ChenPhysiology, Biophysics and Systems Biology Program, Weill Cornell Medicine, New York, New York.
Jacob E TallmanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Syed Muneeb AlamUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jordan E EichholzComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Walid ChatilaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Tejiri AgbamuComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew T LenisUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Merve BasarDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Cansu YolDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jie-Fu ChenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Judy SarungbamDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ying-Bei ChenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Anuradha GopalanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Samson W FineDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Satish K TickooDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Nadeem R Abu-RustumGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Rachel N GrishamGynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Amir Momeni-BoroujeniDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Eugene J PietzakUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Bernard H BochnerUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan E RosenbergGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Gopa IyerGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Victor E ReuterDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
David B SolitGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Hikmat Al-AhmadieDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: alahmadh@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSENBERG, JONATHAN ERIC, SOLIT, DAVID B. · 2018 to 2024
$11.8M
Project 3: Modeling tumor evolution and drug response in bladder cancer organoidsP01CA221757 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEN, MICHAEL M. · 2018 to 2022
$8.6M
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinomaR01CA233899 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AL-AHMADIE, HIKMAT · 2019 to 2023
$2.0M
NCI NIH HHS P01 CA221757NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA221745NCI NIH HHS R01 CA233899
6 · The paper itself

Abstract

Clear cell adenocarcinoma of the urinary tract (utCCA) is a rare, Müllerian-type tumor typically arising in the urethra of female patients with poorly understood pathogenesis. Here, we report the clinical, pathologic, and molecular characterization of a cohort of utCCA treated at a tertiary referral center. Cases were centrally reviewed, and immunohistochemistry and whole exome and targeted sequencing were performed. The landscape of somatic alterations was compared with ovarian and uterine clear cell carcinoma, and urothelial carcinoma. Among 35 utCCA, most patients were female (86%), and the most common primary tumor site was the urethra (83%) in association with urethral diverticula (51%). Median disease-free and overall survival rates were 42 and 65 months, respectively. The most common mutations were in ARID1A and TP53. Mutations in TERT promoter and other chromatin-modifying genes were rare. Phylogenic analysis suggested that utCCA arises from a dysplastic clear cell precursor developing within the diverticular lining. Although this is the largest study of utCCA to date, the study is limited by its small sample size, retrospective design, and clinical heterogeneity of the cohort. Molecular analysis of utCCA, including multiregion sequencing of tumor and adjacent urethral and diverticular lining, supports a potential mechanism of disease pathogenesis in which most utCCA arise from regions of clear cell dysplasia, possibly resulting from chronic inflammation in the setting of urinary stasis, and not through a progression from intestinal metaplasia or divergent differentiation of a precursor urothelial carcinoma.

Indexed as

Adenocarcinoma, Clear CellUrologic NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedMutationRetrospective StudiesBiomarkers, Tumorclear cell adenocarcinomaclear cell carcinomaMülleriannext-generation sequencingurethral cancerurethral diverticulum

Identifiers

PMID40553939
PMCPMC12354236

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.